Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease.
Serum amyloid P component (SAP) is a normal plasma constituent that is observed both in senile plaque and in neurofibrillary tangle in brains of patients with Alzheimer's disease (AD). In this study, we evaluated the SAP levels in cerebrospinal fluid (CSF) of 72 patients with AD, 11 frontotemporal dementia and nine normal control subjects. There was no significant difference in the SAP levels between the AD group and other groups. However, among AD patients, cognitive function was rated using the Mini-Mental State Examination and was correlated with the SAP level (R = 0.38, P < 0.05). Our results suggest that measurement of the SAP levels in CSF can be useful for assessing the degree of cognitive impairment in AD patients.
Kimura
M
M
Department of Psychiatry, National Center Hospital for Mental, Nervous and Muscular Disorders, NCNP, Tokyo, Japan. m-kimura@sa2.so-net.ne.jp
Asada
T
T
Uno
M
M
Machida
N
N
Kasuya
K
K
Taniguchi
Y
Y
Fujita
T
T
Nishiyama
E
E
Iwamoto
N
N
Arai
H
H
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000523:psychology; D003071:Cognition; D003704:Dementia / Q000134:cerebrospinal fluid; D006801:Humans; D008609:Mental Status Schedule; D008875:Middle Aged; D012016:Reference Values; D000683:Serum Amyloid P-Component / Q000134:cerebrospinal fluid*; D016875:tau Proteins / Q000134:cerebrospinal fluid
D000683:Serum Amyloid P-Component; D016875:tau Proteins